| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $1,152 | 2 | 100 |
Sells | $0 | 0 | 0 |
| Nemec Sarah | Senior VP, Finance and PAO | 1 | $576 | 0 | $0 | $576 |
| Quinn William P. | President, CEO and CFO | 1 | $576 | 0 | $0 | $576 |
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Over the last 12 months, insiders at Bolt Biotherapeutics, Inc. have bought $1,152 and sold $0 worth of Bolt Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Bolt Biotherapeutics, Inc. have bought $19,826 and sold $929,707 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Nemec Sarah (Senior VP, Finance and PAO) — $576. Quinn William P. (President, CEO and CFO) — $576.
The last purchase of 125 shares for transaction amount of $576 was made by Quinn William P. (President, CEO and CFO) on 2025‑12‑05.
| 2025-12-05 | Quinn William P. | President, CEO and CFO | 125 0.0055% | $4.61 | $576 | +0.55% | ||
| 2025-12-05 | Nemec Sarah | Senior VP, Finance and PAO | 125 0.0055% | $4.61 | $576 | +0.55% | ||
| 2024-12-16 | Quinn William P. | President, CEO and CFO | 2,500 0.0064% | $0.50 | $1,241 | -40.49% | ||
| 2024-12-16 | Nemec Sarah | Senior VP, Finance and PAO | 2,500 0.0064% | $0.50 | $1,241 | -40.49% | ||
| 2024-06-06 | Quinn William P. | President, CEO and CFO | 2,500 0.0065% | $0.64 | $1,594 | -23.93% | ||
| 2024-06-06 | Nemec Sarah | Senior VP, Finance and PAO | 2,500 0.0065% | $0.64 | $1,594 | -23.93% | ||
| 2023-12-12 | Quinn William P. | Chief Financial Officer | 7,500 0.0291% | $0.95 | $7,125 | -23.90% | ||
| 2023-12-06 | Quinn William P. | Chief Financial Officer | 2,500 0.008% | $0.78 | $1,955 | -17.55% | ||
| 2023-11-30 | Sale | ENGLEMAN EDGAR | director | 123,079 0.4308% | $0.86 | $105,614 | -10.79% | |
| 2023-11-29 | Sale | ENGLEMAN EDGAR | director | 25,805 0.0954% | $0.91 | $23,379 | -14.83% | |
| 2023-11-21 | Sale | ENGLEMAN EDGAR | director | 1,943 0.0071% | $0.90 | $1,751 | -10.78% | |
| 2023-11-21 | Sale | Vivo Capital VIII, LLC | 10 percent owner | 3,400 0.0125% | $0.90 | $3,060 | -10.78% | |
| 2023-11-20 | Sale | ENGLEMAN EDGAR | director | 31,257 0.1173% | $0.92 | $28,756 | -15.33% | |
| 2023-11-20 | Sale | Vivo Capital VIII, LLC | 10 percent owner | 54,700 0.2053% | $0.92 | $50,324 | -15.33% | |
| 2023-11-17 | Sale | ENGLEMAN EDGAR | director | 9,345 0.0354% | $0.93 | $8,691 | -16.40% | |
| 2023-11-17 | Sale | Vivo Capital VIII, LLC | 10 percent owner | 16,354 0.062% | $0.93 | $15,209 | -16.40% | |
| 2023-11-16 | Sale | ENGLEMAN EDGAR | director | 8,571 0.0336% | $0.96 | $8,228 | -16.84% | |
| 2023-11-16 | Sale | Vivo Capital VIII, LLC | 10 percent owner | 15,000 0.0587% | $0.96 | $14,400 | -16.84% | |
| 2023-06-06 | Quinn William P. | Chief Financial Officer | 1,829 0.0088% | $1.18 | $2,161 | -31.48% | ||
| 2022-07-13 | Sale | Novo Holdings A/S | 800,000 6.5259% | $2.00 | $1.6M | -40.32% |
| Quinn William P. | President, CEO and CFO | 2313 0.1205% | $10,061.55 | 10 | 0 | <0.0001% |
| Nemec Sarah | Senior VP, Finance and PAO | 1415 0.0737% | $6,155.25 | 3 | 0 | <0.0001% |
| Novo Holdings A/S | 3703991 192.9724% | $16.11M | 1 | 1 | <0.0001% | |
| HEALY JAMES | director | 2754437 143.502% | $11.98M | 1 | 0 | <0.0001% |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 2754437 143.502% | $11.98M | 1 | 0 | <0.0001% |
| SHAH MAHENDRA | director | 1448286 75.4535% | $6.3M | 0 | 1 | |
| ENGLEMAN EDGAR | director | 251522 13.1039% | $1.09M | 1 | 7 | <0.0001% |
| Vivo Capital VIII, LLC | 10 percent owner | 111662 5.8174% | $485,729.70 | 1 | 5 | <0.0001% |
| Schatzman Randall C | Chief Executive Officer | 1500 0.0781% | $6,525.00 | 1 | 0 | <0.0001% |
| Perez Edith A. | Chief Medical Officer | 1328 0.0692% | $5,776.80 | 2 | 0 | <0.0001% |
| LAPORTE KATHLEEN | director | 1200 0.0625% | $5,220.00 | 1 | 0 | <0.0001% |
| Khanna Ashish Siri Ram | director | 1200 0.0625% | $5,220.00 | 1 | 0 | <0.0001% |
$1,029,337 | 36 | -28.38% | $7.72M | |
$63,749,694 | 24 | -12.24% | $7.66M | |
$1,039,491 | 21 | -11.76% | $6.99M | |
Bolt Biotherapeutics, Inc. (BOLT) | $37,200,153 | 21 | -47.67% | $8.35M |
$6,733,543 | 17 | -19.02% | $9.52M | |
$79,536,861 | 15 | -6.81% | $9.84M | |
$1,246,170 | 12 | 65.67% | $10.58M | |
$188,726 | 11 | -28.87% | $8.42M | |
$20,759,738 | 11 | -44.68% | $9.71M | |
$120,379 | 10 | -24.48% | $7.47M | |
$241,042 | 9 | -11.02% | $8.84M | |
$90,087 | 9 | 20.06% | $9.81M | |
$211,895 | 8 | -39.70% | $7.19M | |
$149,996 | 5 | 16.26% | $8.84M | |
$2,060,158 | 5 | -21.35% | $10.25M | |
$1,184,658 | 4 | -22.17% | $7.96M | |
$28,395 | 3 | 3.48% | $8.07M | |
$1,057,000 | 3 | 5.27% | $6.93M | |
$31,190 | 2 | -14.18% | $7.02M |
| Increased Positions | 7 | +24.14% | 86,402 | +11.18% |
| Decreased Positions | 10 | -34.48% | 287,900 | -37.26% |
| New Positions | 3 | New | 58,756 | New |
| Sold Out Positions | 6 | Sold Out | 159,511 | Sold Out |
| Total Postitions | 26 | -10.34% | 571,233 | -26.08% |
| Vivo Capital, Llc | $1,019.00 | 8.8% | 176,064 | 0 | 0% | 2025-09-30 |
| Sofinnova Investments, Inc. | $797.00 | 6.89% | 137,721 | 0 | 0% | 2025-09-30 |
| Pivotal Bioventure Partners Investment Advisor Llc | $548.00 | 4.73% | 94,573 | 0 | 0% | 2025-09-30 |
| Tang Capital Management Llc | $387.00 | 3.34% | 66,879 | -100,000 | -59.92% | 2025-09-30 |
| Nan Fung Group Holdings Ltd | $338.00 | 2.92% | 58,347 | 0 | 0% | 2025-09-30 |
| Samsara Biocapital, Llc | $283.00 | 2.44% | 48,830 | -3,626 | -6.91% | 2025-09-30 |
| Board Of Trustees Of The Leland Stanford Junior University | $208.00 | 1.8% | 35,978 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $198.00 | 1.71% | 34,231 | -24,253 | -41.47% | 2025-09-30 |
| Renaissance Technologies Llc | $166.00 | 1.43% | 28,625 | +10,300 | +56.21% | 2025-09-30 |
| Geode Capital Management, Llc | $107.00 | 0.93% | 18,533 | 0 | 0% | 2025-09-30 |